International Consensus on Radiotherapy in Metastatic Non-Small Cell Lung Cancer
Zhengfei Zhu,Jianjiao Ni,Xuwei Cai,Shengfa Su,Hongqing Zhuang,Zhenzhou Yang,Ming Chen,Shenglin Ma,Conghua Xie,Yaping Xu,Jiancheng Li,Hong Ge,Anwen Liu,Lujun Zhao,Chuangzhou Rao,Congying Xie,Nan Bi,Zhouguang Hui,Guangying Zhu,Zhiyong Yuan,Jun Wang,Lina Zhao,Wei Zhou,Chai Hong Rim,Arturo Navarro-Martin,Ben G. L. Vanneste,Dirk De Ruysscher,J. Isabelle Choi,Jacek Jassem,Joe Y. Chang,Lucyna Kepka,Lukas Kasmann,Michael T. Milano,Paul Van Houtte,Rafal Suwinski,Alberto Traverso,Hiroshi Doi,Yang-Gun Suh,Georges Noel,Natsuo Tomita,Roman O. Kowalchuk,Terence T. Sio,Baosheng Li,Bing Lu,Xiaolong Fu
DOI: https://doi.org/10.21037/tlcr-22-644
2022-01-01
Translational Lung Cancer Research
Abstract:Background:Lung cancer is the leading cause of cancer-related death worldwide, with non-small cell lung cancer (NSCLC) accounting for most cases. While radiotherapy has historically served as a palliative modality in metastatic NSCLC, considerable advances in its technology and the continuous development of cutting-edge therapeutic agents, such as targeted therapy and immune checkpoint inhibitors (ICIs), are increasing its role in the multi-disciplinary management of the disease.Methods:International radiotherapy experts were convened to consider and reach consensuses on the clinical utilities of radiotherapy in metastatic NSCLC, with the aim to provide patient-focused, up to date, evidence-based, recommendations to assist cancer specialists in the management of patients with metastatic NSCLC worldwide.Results:Timely radiotherapy can offer rapid symptom alleviation and allow subsequent aggressive treatment approaches in patients with heavy tumor burden and/or oncologic emergencies. In addition, appropriate incorporation of radiotherapy as concurrent, consolidation, or salvage therapy makes it possible to achieve long-term survival, or even cure, for patients with oligo-metastatic disease. Cranial radiotherapy plays an important role in the management of brain metastasis, potentially augmenting the response and prolonging survival associated with targeted agents and ICIs. However, key questions remain, such as the appropriate choice of radiation techniques, optimal sequence of systemic therapies and radiotherapy, and optimal patient selection for such combination strategies. Although a strong rationale for combining radiotherapy and ICIs exists, its optimal parameters in this setting remain to be established.Conclusions:In the modern era, radiotherapy serves not only as a palliative tool in metastatic NSCLC, but also plays active roles in patients with oligo-focal disease, CNS metastasis and receiving ICIs.